{
  "trial_id": "NCT02538510",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, gender, race, ECOG performance status, primary cancer site, stage of cancer, prior lines of systemic therapy, absolute neutrophil count (ANC), platelet count, hemoglobin level, serum creatinine level, creatinine clearance, serum total bilirubin, aspartate aminotransferase (AST) level, alanine aminotransferase (ALT) level, international normalized ratio (INR), activated partial thromboplastin time (aPTT), pregnancy status (for females of childbearing potential), use of contraception (for both males and females of childbearing potential), history of other primary malignancies, history of autoimmune disease, history of CNS metastases, history of interstitial lung disease or pneumonitis, history of active infections, history of psychiatric or substance abuse disorders, history of HIV, hepatitis B, or hepatitis C, prior therapy with anti-PD-1, PD-L1, PD-L2, CD137, CTLA-4 antibodies, prior therapy with vorinostat or other epigenetic agents, receipt of live vaccines within 30 days prior to trial treatment, ability to swallow pills or take suspension through a gastrostomy tube.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "gender"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Ethnicity (NIH/OMB)",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "ECOG performance status",
        "primary cancer site",
        "stage of cancer",
        "prior lines of systemic therapy",
        "absolute neutrophil count (ANC)",
        "platelet count",
        "hemoglobin level",
        "serum creatinine level",
        "creatinine clearance",
        "serum total bilirubin",
        "aspartate aminotransferase (AST) level",
        "alanine aminotransferase (ALT) level",
        "international normalized ratio (INR)",
        "activated partial thromboplastin time (aPTT)",
        "pregnancy status (for females of childbearing potential)",
        "use of contraception (for both males and females of childbearing potential)",
        "history of other primary malignancies",
        "history of autoimmune disease",
        "history of CNS metastases",
        "history of interstitial lung disease or pneumonitis",
        "history of active infections",
        "history of psychiatric or substance abuse disorders",
        "history of HIV",
        "hepatitis B",
        "or hepatitis C",
        "prior therapy with anti-PD-1",
        "PD-L1",
        "PD-L2",
        "CD137",
        "CTLA-4 antibodies",
        "prior therapy with vorinostat or other epigenetic agents",
        "receipt of live vaccines within 30 days prior to trial treatment",
        "ability to swallow pills or take suspension through a gastrostomy tube."
      ]
    }
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Performance Status (ECOG), Absolute Neutrophil Count (ANC), Platelet Count, Hemoglobin Level, Serum Creatinine, Creatinine Clearance, Serum Total Bilirubin, Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), International Normalized Ratio (INR), Prothrombin Time (PT), Activated Partial Thromboplastin Time (aPTT), Tumor Type, Prior Lines of Therapy, Measurable Disease Based on RECIST 1.1,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race (NIH/OMB)",
          "Race/Ethnicity"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Ethnicity (NIH/OMB)"
      ],
      "remaining_candidate_features": [
        "Performance Status (ECOG)",
        "Absolute Neutrophil Count (ANC)",
        "Platelet Count",
        "Hemoglobin Level",
        "Serum Creatinine",
        "Creatinine Clearance",
        "Serum Total Bilirubin",
        "Aspartate Aminotransferase (AST)",
        "Alanine Aminotransferase (ALT)",
        "International Normalized Ratio (INR)",
        "Prothrombin Time (PT)",
        "Activated Partial Thromboplastin Time (aPTT)",
        "Tumor Type",
        "Prior Lines of Therapy",
        "Measurable Disease Based on RECIST 1.1"
      ]
    }
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, ECOG Performance Status, Prior Systemic Therapy, Prior Radiation Therapy, Tumor Site, Tumor Stage, Histology, Prior Surgery, Prior Chemotherapy, Prior Targeted Therapy, Prior Immunotherapy, Prior Radiation Therapy, Absolute Neutrophil Count, Platelets, Hemoglobin, Serum Creatinine, Serum Total Bilirubin, AST, ALT, INR, aPTT, Pregnancy Status.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Ethnicity (NIH/OMB)",
          "Race/Ethnicity"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Race (NIH/OMB)"
      ],
      "remaining_candidate_features": [
        "ECOG Performance Status",
        "Prior Systemic Therapy",
        "Prior Radiation Therapy",
        "Tumor Site",
        "Tumor Stage",
        "Histology",
        "Prior Surgery",
        "Prior Chemotherapy",
        "Prior Targeted Therapy",
        "Prior Immunotherapy",
        "Absolute Neutrophil Count",
        "Platelets",
        "Hemoglobin",
        "Serum Creatinine",
        "Serum Total Bilirubin",
        "AST",
        "ALT",
        "INR",
        "aPTT",
        "Pregnancy Status"
      ]
    }
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, ECOG performance status, primary tumor site, histology, prior systemic therapy, prior radiation therapy, time from diagnosis to study enrollment, time from last systemic therapy to study enrollment, absolute neutrophil count, platelets, hemoglobin, serum creatinine, serum total bilirubin, AST, ALT, INR, aPTT, presence of metastatic disease, number of metastatic sites.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "Ethnicity (NIH/OMB)",
          "ethnicity"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "ECOG performance status",
        "primary tumor site",
        "histology",
        "prior systemic therapy",
        "prior radiation therapy",
        "time from diagnosis to study enrollment",
        "time from last systemic therapy to study enrollment",
        "absolute neutrophil count",
        "platelets",
        "hemoglobin",
        "serum creatinine",
        "serum total bilirubin",
        "AST",
        "ALT",
        "INR",
        "aPTT",
        "presence of metastatic disease",
        "number of metastatic sites"
      ]
    }
  }
}